Kiyoshi Nobori
About Kiyoshi Nobori
Kiyoshi Nobori serves as the Senior Director and Head of Clinical Development for Insmed Incorporated in Japan. With over 20 years of experience in drug therapy and a strong background in clinical research, he has contributed significantly to the field, particularly in cardiology and drug development.
Work at Insmed
Kiyoshi Nobori serves as the Senior Director and Head of Clinical Development for Japan at Insmed Incorporated. He has held this position since 2022, overseeing clinical development initiatives and strategies within the Japanese market. His role involves managing clinical trials and regulatory submissions, contributing to the advancement of therapeutic options in the region.
Education and Expertise
Kiyoshi Nobori earned his Doctor of Medicine (MD) from Shinsyu University, where he studied from 1991 to 1997. He later pursued a Doctor of Philosophy (PhD) in Cardiology at Tokyo Medical and Dental University, completing his studies from 2000 to 2004. His educational background supports his extensive expertise in cardiovascular medicine and clinical research.
Background
Kiyoshi Nobori has a diverse professional background in clinical research and cardiology. He began his career as a Resident Doctor at Shinshu University from 1997 to 1998. He then worked as a Cardiologist at Tokyo Medical and Dental University from 2000 to 2004, followed by an Associate Professor role at the same institution from 2016 to 2018. He also served as a Postdoctoral Researcher at Baylor College of Medicine from 2004 to 2006.
Achievements
Kiyoshi Nobori has published five papers focused on the drug Molidustat. He has significant experience in regulatory roles, having worked as a reviewer for the Pharmaceuticals and Medical Devices Agency (PMDA) for seven years. During his career, he led clinical teams that successfully filed two New Drug Applications (NDAs) and one supplemental NDA (sNDA), resulting in approvals for Molidustat and Vericiguat in 2021, and Xarelto PAD in 2022.
Clinical Research Contributions
Throughout his career, Kiyoshi Nobori has supported investigator-initiated clinical trials and provided consultation on clinical development plans for drug repositioning, new medical devices, and regenerative therapies. His background includes basic research projects involving apoptosis, cell cycle, autophagy, cardiac hypertrophy, and regeneration therapy, demonstrating his commitment to advancing medical knowledge and patient care.